DUBLIN, September 23, 2022 /PRNewswire/ — Added “Global Markets for Insulin Pharmaceuticals and Delivery Technologies” report of ResearchAndMarkets.com offer.
The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes data for 2021, forecasts for 2022, projections of compound annual growth rates to 2027 (forecast period 2022-2027), and regional markets for insulin drug and delivery technologies, and market trends for insulin drug and delivery technologies.
This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive landscape. The current report will address regulatory scenarios, drivers, constraints and opportunities. The report also includes market forecasts for 2026 and market share for key market players.
Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Purpose-built insulin delivery devices, such as smart pens, help diabetics optimize blood sugar control and minimize the risk of associated health problems. Advanced insulin delivery devices offer better patient compliance.
Traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens due to their portability, higher dosing accuracy, internal memory, larger dosages and ease of use. There has been no significant improvement over conventional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG, and B. Braun Melsungen AG. Major manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon, and Viatris Inc.
The market growth is attributed to factors such as the increasing incidence of diabetes and new insulin drug and delivery technologies. The global market for insulin drug and delivery technologies is segmented by device type, insulin type, and region.
In this report, the market is segmented by device type, insulin type, and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens, and others. Types of insulin include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting insulins.
Geographical regions covered include: North America, Europe, Asia Pacific and the rest of the world (RoW). Individual countries covered include the USA, GermanyUnited Kingdom, Italy, France, Japan, Chinese and India.
Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
- 24 data tables and 31 additional tables
- A current review of global markets for insulin drug and delivery technologies
- Analysis of global market trends with historical market revenue (sales data) for 2020 and 2021, forecasts for 2022, and projections of compound annual growth rates (CAGRs) to 2027
- Highlights of the current state of the insulin drug and delivery industry structure, new technology updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
- Estimation of actual market size and market forecast for insulin drug and delivery technologies and related market share analysis by device type, insulin type, and geographic region
- Up-to-date information on key M&A deals, partnerships, collaborations and other strategic alliances in the insulin pharmaceutical and delivery technology industry
- Analysis of market opportunities with a holistic review of Porter’s Five Forces analysis model that considers both micro and macro environmental factors prevailing in the market
- Identifying the main stakeholders and analyzing the competitive environment based on the latest developments and segment revenues
Key Topics Covered:
Chapter 1 Introduction
1.1 Insulin Overview
1.2 Diabetes Overview
1.2.1 Disease Symptoms and Risk Factors
1.2.2 Epidemiology and Economic Burden
1.3 Study Objectives and Objectives
1.4 Reasons for Conducting This Study
1.5 What’s New in This Update?
1.6 Scope of the Report
1.7 Information Resources
1.9 Geographical Casting
1.10 Analyst’s Credentials
1.11 Special Research
1.12 Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Increasing Prevalence of Diabetes
3.1.2 Smart Insulin Drug Delivery Technologies
3.1.3 Painless Insulin Drug Administration Technologies
3.2 Market Restrictions
3.2.1 Product Recall
3.3 Market Opportunities
3.3.1 Inorganic Strategies Among Market Players
Chapter 4 Market Overview
4.1 Market Information
4.2 Current Market Trends
4.2.1 Final Product Introductions
4.2.2 Recent Strategic Alliances
4.3 Future Perspective
Chapter 5 Regulatory Landscape and Payback Scenario
5.1 Regulatory Landscape
5.1.1 US Regulations for Medical Devices
5.1.2 US Drug Regulations
5.1.3 European Regulations for Medical Devices
5.1.4 European Drug Regulations
5.1.5 Asia-Pacific Regulations for Medical Devices
5.2 Payback Scenario
5.2.1 Pricing and Refund Overview
5.2.2 Pricing and Reimbursement for Medical Devices
5.2.3 Pricing and Reimbursement for Medicines
5.3.1 Insurance for Diabetic Emergencies
Chapter 6 Impact of Covid-19 on the Market
6.2 Covid-19 Crisis
6.2.1 Impact on Insulin Pharmaceuticals and Administration Technologies Market
6.2.2 Covid-19 Precautions
Chapter 7 Market Breakdown by Device Type
7.1 Insulin Delivery Technologies
7.1.2 Insulin Pens
7.1.3 Insulin Pumps
7.1.4 Smart Pens
Chapter 8 Market Breakdown by Type of Insulin
8.1.1 Structure of Insulin
8.1.2 Insulin Biosynthesis
8.1.3 Types of Insulin
Chapter 9 Market Breakdown by Region
9.1.1 North America
9.1.3 Asia Pacific
9.1.4 Rest of the World
Chapter 10 Analysis of Market Opportunities
10.1 Porter’s Five Force Analysis
10.1.1 Threat of New Entrants
10.1.2 Substitute Threat
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition
Chapter 11 Competitive Environment
Chapter 12 Company Profiles
12.1 Large Corporations
- B.Braun Melsungen AG
- Becton, Dickinson and Co.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Medtronic Inc.
- Novo Nordisk A/S
- Viatris Inc.
- Ypsomed Holding AG
- Other companies
- Cequr Simplicity
- Debiotech SA
- Emperra GmbH E-Health Technologies
- Insulet Corp.
- Nanopass Technologies Ltd.
- Nipro Medical Corp.
- Owen Mumford Ltd.
- Tandem Diabetes Care Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/qw0qyx.
Research and Markets
Laura Woodsenior manager
Call +1-917-300-0470 for EST Hours of Operation
US/CAN Toll Free Call +1-800-526-8630
For GMT Business Hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets